JP2010518811A5 - - Google Patents

Download PDF

Info

Publication number
JP2010518811A5
JP2010518811A5 JP2009548433A JP2009548433A JP2010518811A5 JP 2010518811 A5 JP2010518811 A5 JP 2010518811A5 JP 2009548433 A JP2009548433 A JP 2009548433A JP 2009548433 A JP2009548433 A JP 2009548433A JP 2010518811 A5 JP2010518811 A5 JP 2010518811A5
Authority
JP
Japan
Prior art keywords
expression level
cancer cells
cancer
biomarker
tm4sf4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009548433A
Other languages
English (en)
Japanese (ja)
Other versions
JP5670055B2 (ja
JP2010518811A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/052540 external-priority patent/WO2008095050A1/en
Publication of JP2010518811A publication Critical patent/JP2010518811A/ja
Publication of JP2010518811A5 publication Critical patent/JP2010518811A5/ja
Application granted granted Critical
Publication of JP5670055B2 publication Critical patent/JP5670055B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009548433A 2007-01-30 2008-01-30 ヒストンデアセチラーゼ阻害剤に対する癌の耐性を決定する方法 Expired - Fee Related JP5670055B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88731807P 2007-01-30 2007-01-30
US60/887,318 2007-01-30
US91185507P 2007-04-13 2007-04-13
US60/911,855 2007-04-13
PCT/US2008/052540 WO2008095050A1 (en) 2007-01-30 2008-01-30 Methods for determining cancer resistance to histone deacetylase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014125267A Division JP2014221049A (ja) 2007-01-30 2014-06-18 ヒストンデアセチラーゼ阻害剤に対する癌の耐性を決定する方法

Publications (3)

Publication Number Publication Date
JP2010518811A JP2010518811A (ja) 2010-06-03
JP2010518811A5 true JP2010518811A5 (enExample) 2011-03-17
JP5670055B2 JP5670055B2 (ja) 2015-02-18

Family

ID=39674490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009548433A Expired - Fee Related JP5670055B2 (ja) 2007-01-30 2008-01-30 ヒストンデアセチラーゼ阻害剤に対する癌の耐性を決定する方法
JP2014125267A Pending JP2014221049A (ja) 2007-01-30 2014-06-18 ヒストンデアセチラーゼ阻害剤に対する癌の耐性を決定する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014125267A Pending JP2014221049A (ja) 2007-01-30 2014-06-18 ヒストンデアセチラーゼ阻害剤に対する癌の耐性を決定する方法

Country Status (10)

Country Link
US (3) US7838234B2 (enExample)
EP (2) EP2993473A1 (enExample)
JP (2) JP5670055B2 (enExample)
KR (1) KR101483805B1 (enExample)
CN (1) CN101657217B (enExample)
AU (2) AU2008210421B2 (enExample)
CA (1) CA2677000A1 (enExample)
EA (2) EA201201640A1 (enExample)
NZ (1) NZ579048A (enExample)
WO (1) WO2008095050A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120090100A (ko) 2006-12-26 2012-08-16 파마시클릭스, 인코포레이티드 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
US7838234B2 (en) * 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
DE102008000715B9 (de) * 2008-03-17 2013-01-17 Sirs-Lab Gmbh Verfahren zur in vitro Erfasssung und Unterscheidung von pathophysiologischen Zuständen
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US20140243403A1 (en) * 2011-06-03 2014-08-28 The General Hospital Corporation Treating colorectal, pancreatic, and lung cancer
KR101384667B1 (ko) * 2011-09-09 2014-04-21 강원대학교산학협력단 항암제인 택솔에 대한 민감성 여부를 판명하는 인자로서의 히스톤 탈아세틸화 효소 3의 용도
CA2845806C (en) 2011-09-13 2019-06-11 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
WO2013071247A1 (en) * 2011-11-10 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Gene expression signatures of neoplasm responsiveness to theraphy
AP2014007796A0 (en) 2011-12-22 2014-07-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN102532298B (zh) * 2012-03-01 2013-11-06 刘林林 与自身抗体特异性结合的abcc3抗原多肽及应用
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
EP2839037B1 (en) * 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
AU2013202506B2 (en) * 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
JP6749589B2 (ja) * 2015-07-31 2020-09-02 国立大学法人北海道大学 抗Ｅｖａ１タンパク質抗体
CN106467914A (zh) * 2015-08-18 2017-03-01 华东理工大学 靶向人TSPAN8基因的siRNA及其应用
US11015226B2 (en) * 2015-10-06 2021-05-25 Ontario Institute For Cancer Research (Oicr) Targeting the histone pathway to detect and overcome anthracyclin resistance
WO2017070441A1 (en) * 2015-10-23 2017-04-27 Icahn School Of Medicine At Mount Sinai Identifying and treating cancer patients who are suitable for a targeted therapy using an hdac6 inhibitor
US10591462B2 (en) 2016-03-03 2020-03-17 Mohammad Abdolahad Electrochemical method and device for detecting the effect of anticancer drugs
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
CN106755464A (zh) * 2017-01-11 2017-05-31 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
CN108300783A (zh) * 2017-01-11 2018-07-20 上海易毕恩基因科技有限公司 用于筛选肠癌和/或胃癌的基因标志物的方法、用该方法筛选的基因标志物及其用途
US20190046513A1 (en) * 2017-08-10 2019-02-14 Huya Bioscience International, Llc Combination therapies of hdac inhibitors and tubulin inhibitors
CN115044667A (zh) * 2018-09-21 2022-09-13 王赞鑫 与主动脉夹层疾病相关的snp位点及其应用
MX2022001812A (es) 2019-08-12 2022-03-11 Regeneron Pharma Variantes del receptor estimulante de macrofagos 1 (mst1r) y sus usos.
CN114829375A (zh) * 2019-10-07 2022-07-29 维拉克塔附属公司 具有降低的副作用的hdac治疗的剂量
EP3821890A1 (en) * 2019-11-18 2021-05-19 Strumberg, Dirk Pharmaceutical compositions comprising an inhibitor of a histon-deacetylase (hdaci) and an agonist of toll-like-receptor 7 and/or 8 (tlr7 and/or tlr8) and their use in the treatment of cancer
EP4133108A1 (en) * 2020-04-09 2023-02-15 Turun yliopisto Eplin as a biomarker for cancer
WO2024128867A1 (ko) * 2022-12-16 2024-06-20 한국원자력연구원 항-tm4sf4 인간화 항체 및 이의 용도
CN118743746B (zh) * 2024-06-05 2025-06-06 中国农业大学 Clic5基因或clic5蛋白在制备治疗代谢综合征的药物中的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794063A (fr) 1972-01-17 1973-07-16 Henkel & Cie Gmbh Anti-inflammatoires pour compositions cosmetiques
EP0084236A3 (en) 1981-12-22 1983-08-03 Fbc Limited Fungicidal heterocyclic compounds and compositions containing them
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
EP0394440B1 (en) 1987-10-20 1994-05-11 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5045694A (en) 1989-09-27 1991-09-03 The Rockefeller University Instrument and method for the laser desorption of ions in mass spectrometry
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
JPH03215470A (ja) 1990-01-22 1991-09-20 Suntory Ltd プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
DE4019005C2 (de) 1990-06-13 2000-03-09 Finnigan Mat Gmbh Vorrichtungen zur Analyse von Ionen hoher Masse
DE4124345A1 (de) 1991-07-23 1993-01-28 Gruenenthal Gmbh Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
ATE173767T1 (de) 1992-04-03 1998-12-15 Perkin Elmer Corp Proben zusammensetzung und verfahren
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
DE4327365A1 (de) 1993-08-14 1995-02-16 Boehringer Mannheim Gmbh Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
US6040139A (en) 1995-09-19 2000-03-21 Bova; G. Steven Laser cell purification system
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
JP2000504575A (ja) 1996-02-08 2000-04-18 アフィメトリックス，インコーポレイテッド 微生物のチップベースの種分化および表現型特徴付け
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US5777324A (en) 1996-09-19 1998-07-07 Sequenom, Inc. Method and apparatus for maldi analysis
US5953727A (en) 1996-10-10 1999-09-14 Incyte Pharmaceuticals, Inc. Project-based full-length biomolecular sequence database
WO1999005574A1 (en) 1997-07-25 1999-02-04 Affymetrix, Inc. Method and system for providing a probe array chip design database
US6211197B1 (en) 1998-10-07 2001-04-03 Merck Frosst Canada & Co. Prostaglandin receptor ligands
WO2001014331A2 (en) 1999-08-24 2001-03-01 Regents Of The University Of California Non-quinoline inhibitors of malaria parasites
ATE514674T1 (de) 1999-11-23 2011-07-15 Methylgene Inc Inhibitoren für histone-deacetylase
CA2423744C (en) 2000-09-29 2012-04-03 Prolifix Limited Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
GB0023983D0 (en) 2000-09-29 2000-11-15 Prolifix Ltd Therapeutic compounds
MX242553B (es) 2000-10-20 2006-12-06 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
JP2004527229A (ja) * 2000-12-28 2004-09-09 エピダウロス バイオテクノロジー アクツィエンゲゼルシャフト 多型ｃｙｐ３ａ５発現の遺伝的決定基の同定
ATE485515T1 (de) * 2001-06-22 2010-11-15 Burkhard Jansen Verfahren zur diagnose einer person mit multipler sklerose
US7247426B2 (en) * 2001-08-02 2007-07-24 Agilent Technologies, Inc. Classifying cancers
ITMI20011733A1 (it) 2001-08-07 2003-02-07 Italfarmaco Spa Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
HU229521B1 (hu) * 2001-08-21 2014-01-28 Astellas Pharma Inc A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20030166026A1 (en) * 2002-01-09 2003-09-04 Lynx Therapeutics, Inc. Identification of specific biomarkers for breast cancer cells
AU2003244498A1 (en) * 2002-02-04 2003-09-02 Epidauros Biotechnologie Ag Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications
AU2003211362A1 (en) 2002-02-21 2003-09-09 Osaka Industrial Promotion Organization N-hydroxycarboxamide derivative
US20060276547A1 (en) * 2002-03-04 2006-12-07 Bacopoulos Nicholas G Methods of treating cancer with HDAC inhibitors
US7371207B2 (en) * 2002-04-12 2008-05-13 Wyeth Estrogen receptor α regulated gene expression, related assays and therapeutics
JP3856734B2 (ja) * 2002-06-28 2006-12-13 株式会社日立製作所 多発性硬化症に対するインターフェロン・ベータ薬物治療の有効性予測方法
CA2494114A1 (en) 2002-08-02 2004-02-12 Argenta Discovery Limited Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
EP1400806A1 (en) 2002-09-18 2004-03-24 G2M Cancer Drugs AG The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
EP1595952A4 (en) 2003-02-19 2008-05-21 Astellas Pharma Inc METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
WO2004081174A2 (ja) * 2003-03-10 2004-09-23 Japan Science And Technology Agency 間葉系幹細胞検出用マーカー及び該マーカーを用いた間葉系幹細胞の識別方法
WO2004092115A2 (en) 2003-04-07 2004-10-28 Axys Pharmaceuticals Inc. Hydroxamates as therapeutic agents
KR20060031809A (ko) * 2003-06-09 2006-04-13 더 리젠츠 오브 더 유니버시티 오브 미시간 암 치료 및 진단용 조성물 및 방법
WO2005043161A2 (en) * 2003-11-04 2005-05-12 Roche Diagnostics Gmbh Method for distinguishing leukemia subtypes
EP1694866A4 (en) 2003-12-12 2007-12-26 Bayer Pharmaceuticals Corp GENE EXPRESSION PROFILES AND METHODS OF USE
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
AU2005267756A1 (en) * 2004-07-30 2006-02-09 Rosetta Inpharmatics Llc Prognosis of breast cancer patients
DE102005011957A1 (de) * 2005-03-14 2006-12-07 Henkel Kgaa Neues Haarbehandlungsmittel, enthaltend L-Carnitin oder L-Carnitinderivate
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US7838234B2 (en) 2007-01-30 2010-11-23 Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors
UY34295A (es) 2011-09-08 2013-04-30 Servier Lab Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida

Similar Documents

Publication Publication Date Title
JP2010518811A5 (enExample)
D’Errico et al. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability
US11174518B2 (en) Method of classifying and diagnosing cancer
ES2862331T3 (es) Métodos para predecir el estado de los genes BRCA1 y BRCA2 en una célula de cáncer
US20220049312A1 (en) microRNAs as Biomarkers for Endometriosis
JP2012500389A5 (enExample)
Hélias-Rodzewicz et al. Variations of BRAF mutant allele percentage in melanomas
JP2014519813A5 (enExample)
JP7043404B2 (ja) 早期乳癌における内分泌処置後の残留リスクの遺伝子シグネチャー
US20110086348A1 (en) Method for assessing heart disease
JP2018504915A5 (enExample)
CN110168106B (zh) 预测进展期胃癌患者的术后预后或抗癌药物适合性的系统
US20210404002A1 (en) Quantitative Algorithm for Endometriosis
US11993816B2 (en) Circulating microRNA as biomarkers for endometriosis
JP2010538609A5 (enExample)
AU2017228649A1 (en) Methods for predicting drug responsiveness in cancer patients
JP2020535827A (ja) マイクロｒｎａ遺伝子発現を使用して黒色腫を診断し、病期分類し、モニタリングする方法
EP3186394B1 (en) Detection of melanoma
CN115701286A (zh) 使用无循环mRNA谱分析检测阿尔茨海默病风险的系统和方法
JP2008512984A5 (enExample)
JP2019533987A5 (enExample)
AU2018315434A1 (en) Materials and methods for stratifying and treating cancers
CN111315897B (zh) 用于黑素瘤检测的方法
US9469852B2 (en) Methods and compositions using miR-3151 in the diagnosis and treatment of cancer
US11814685B2 (en) Diagnosis and/or prognosis of HER2-dependent cancer using one or more miRNA as a biomarker